Exigency of Plant-Based Vaccine against COVID-19 Emergence as Pandemic Preparedness DOI Creative Commons
Anirudha Chattopadhyay,

A. Abdul Kader Jailani,

Bikash Mandal

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(8), P. 1347 - 1347

Published: Aug. 9, 2023

After two years since the declaration of COVID-19 as a pandemic by World Health Organization (WHO), more than six million deaths have occurred due to SARS-CoV-2, leading an unprecedented disruption global economy. Fortunately, within year, wide range vaccines, including pathogen-based inactivated and live-attenuated replicating non-replicating vector-based nucleic acid (DNA mRNA)-based protein-based subunit virus-like particle (VLP)-based been developed mitigate severe impacts pandemic. These vaccines proven highly effective in reducing severity illness preventing deaths. However, availability supply become issue prioritization vaccine distribution most countries. Additionally, virus continues mutate spread, questions arisen regarding effectiveness against new strains SARS-CoV-2 that can evade host immunity. The urgent need for booster doses enhance immunity has recognized. scarcity “safe effective” exacerbated inequalities terms coverage. development fallen short expectations set forth 2020 2021. Furthermore, equitable at national levels remains challenge, particularly developing In such circumstances, exigency plant virus-based apparent means overcome shortages through fast manufacturing processes enable quick convenient millions people without reliance on cold chain system. Moreover, demonstrated both safety efficacy eliciting robust cellular immunogenicity pathogens. This review aims shed light advantages disadvantages different types provide update current status plant-based fight

Language: Английский

Immunomodulatory biomaterials against bacterial infections: Progress, challenges, and future perspectives DOI Creative Commons
Shutao Zhang, Hongtao Yang, Minqi Wang

et al.

The Innovation, Journal Year: 2023, Volume and Issue: 4(6), P. 100503 - 100503

Published: Aug. 29, 2023

•Insights into the intricate facets of immune microenvironment hold key to pioneering clinical strategies in combatting bacterial infections.•The design principles for antimicrobial biomaterials vary depending on at different stages infection.•Immunomodulatory display robust efficacy and vaccine attributes animals trials, promising intractable infections. Bacterial infectious diseases are one leading causes death worldwide. Even with use multiple antibiotic treatment strategies, 4.95 million people died from drug-resistant infections 2019. By 2050, number deaths will reach 10 annually. The increasing mortality may be partly due heterogeneity infection microenvironment, such as bacteria, biofilms, persister cells, intracellular small colony variants. In addition, complexity makes direct activity unsatisfactory long-term chronic attributed failing modulate active action cells. Therefore, there is an urgent need effective alternatives treat Accordingly, development immunomodulatory has recently received considerable interest; however, a comprehensive review their research progress lacking. this review, we focus mainly future perspectives used infection. First, describe characteristics acute phases Then, highlight corresponding advantages disadvantages. Moreover, discuss biomaterial-mediated vaccines' potential applications challenges activating innate adaptive memory. This serve reference studies develop next-generation accelerate translation practice.

Language: Английский

Citations

65
Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines DOI Creative Commons
Xanthippi Topalidou, Alexis M. Kalergis, Georgios Papazisis

et al.

Pathogens, Journal Year: 2023, Volume and Issue: 12(10), P. 1259 - 1259

Published: Oct. 19, 2023

Respiratory syncytial virus (RSV) is responsible for a significant proportion of global morbidity and mortality affecting young children older adults. In the aftermath formalin-inactivated RSV vaccine development, effort to develop an immunizing agent was carefully guided by epidemiologic pathophysiological evidence virus, including various technologies. The pipeline development includes messenger ribonucleic acid (mRNA), live-attenuated (LAV), subunit, recombinant vector-based candidates targeting different proteins. availability technologies enables adjustment individualized needs each vulnerable age group. Arexvy® (GSK), followed Abrysvo® (Pfizer), first available market use as prevent lower respiratory tract disease in Abrysvo additionally indicated passive immunization infants maternal administration during pregnancy. This review presents pipeline, analyzing results clinical trials. key features technology are also mentioned. Currently, 24 vaccines stage 2 licensed vaccines. Research field vaccination, pharmacovigilance methods already approved vaccines, promotes achievement successful prevention.

Language: Английский

Citations

62
Protein subunit vaccines: Promising frontiers against COVID-19 DOI
Vivek P. Chavda, Eswara Naga Hanuma Kumar Ghali, Pankti C. Balar

et al.

Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 366, P. 761 - 782

Published: Jan. 20, 2024

Language: Английский

Citations

19
Chitosan immunomodulation: insights into mechanisms of action on immune cells and signaling pathways DOI Creative Commons
Majed Ghattas, Garima Dwivedi, Anik Chevrier

et al.

RSC Advances, Journal Year: 2025, Volume and Issue: 15(2), P. 896 - 909

Published: Jan. 1, 2025

Chitosan, a biodegradable and biocompatible natural polymer, modulates the activation of antigen-presenting immune cells.

Language: Английский

Citations

8
Advances in nucleic acid-based cancer vaccines DOI Creative Commons
Hung‐Chun Liao, Shih‐Jen Liu

Journal of Biomedical Science, Journal Year: 2025, Volume and Issue: 32(1)

Published: Jan. 21, 2025

Abstract Nucleic acid vaccines have emerged as crucial advancements in vaccine technology, particularly highlighted by the global response to COVID-19 pandemic. The widespread administration of mRNA against billions globally marks a significant milestone. Furthermore, approval an for Respiratory Syncytial Virus (RSV) this year underscores versatility technology. In oncology, combination encoding neoantigens and immune checkpoint inhibitors (ICIs) has shown remarkable efficacy eliciting protective responses diseases like melanoma pancreatic cancer. Although use DNA been limited India, inherent stability at room temperature cost-effectiveness present viable option that could benefit developing countries. These advantages may help address some challenges associated with vaccines. Currently, several trials are exploring DNA-encoded ICIs across various cancer types. studies highlight promising role nucleic acid-based next generation immunotherapeutic agents treatment. This review will delve into recent current developmental status both DNA-based

Language: Английский

Citations

5
Tuberculosis vaccines and therapeutic drug: challenges and future directions DOI Creative Commons

Yajing An,

Ruizi Ni,

Zhuang Li

et al.

Molecular Biomedicine, Journal Year: 2025, Volume and Issue: 6(1)

Published: Jan. 22, 2025

Abstract Tuberculosis (TB) remains a prominent global health challenge, with the World Health Organization documenting over 1 million annual fatalities. Despite deployment of Bacille Calmette-Guérin (BCG) vaccine and available therapeutic agents, escalation drug-resistant Mycobacterium tuberculosis strains underscores pressing need for more efficacious vaccines treatments. This review meticulously maps out contemporary landscape TB development, focus on antigen identification, clinical trial progress, obstacles future trajectories in research. We spotlight innovative approaches, such as multi-antigen mRNA technology platforms. Furthermore, delves into current therapeutics, particularly multidrug-resistant (MDR-TB), exploring promising agents like bedaquiline (BDQ) delamanid (DLM), well potential host-directed therapies. The hurdles development encompass overcoming diversity, enhancing effectiveness across diverse populations, advancing novel Future initiatives emphasize combinatorial strategies, anti-TB compounds targeting pathways, personalized medicine treatment prevention. notable advances, persistent challenges diagnostic failures protracted regimens continue to impede progress. work aims steer research endeavors toward groundbreaking providing crucial insights prevention strategies.

Language: Английский

Citations

4
Cancer vaccines: current status and future directions DOI Creative Commons
Yi Zhou, Yuquan Wei, Xiaohe Tian

et al.

Journal of Hematology & Oncology, Journal Year: 2025, Volume and Issue: 18(1)

Published: Feb. 17, 2025

Cancer continues to be a major global health burden, with high morbidity and mortality. Building on the success of immune checkpoint inhibitors adoptive cellular therapy, cancer vaccines have garnered significant interest, but their clinical remains modest. Benefiting from advancements in technology, many meticulously designed shown promise, warranting further investigations reach full potential. hold unique benefits, particularly for patients resistant other therapies, they offer ability initiate broad durable T cell responses. In this review, we highlight antigen selection vaccines, introduce responses induced by propose strategies enhance vaccine immunogenicity. Furthermore, summarize key features notable advances various platforms. Lastly, delve into mechanisms tumor resistance explore potential benefits combining standard treatments immunomodulatory approaches improve efficacy.

Language: Английский

Citations

3
Molecular Farming for Immunization: Current Advances and Future Prospects in Plant-Produced Vaccines DOI Creative Commons
Dang-Khoa Vo, Kieu The Loan Trinh

Vaccines, Journal Year: 2025, Volume and Issue: 13(2), P. 191 - 191

Published: Feb. 15, 2025

Using plants as bioreactors, molecular farming has emerged a versatile and sustainable platform for producing recombinant vaccines, therapeutic proteins, industrial enzymes, nutraceuticals. This innovative approach leverages the unique advantages of plants, including scalability, cost-effectiveness, reduced risk contamination with human pathogens. Recent advancements in gene editing, transient expression systems, nanoparticle-based delivery technologies have significantly enhanced efficiency versatility plant-based systems. Particularly vaccine development, demonstrated its potential notable successes such Medicago's Covifenz COVID-19, illustrating capacity platforms to address global health emergencies rapidly. Furthermore, edible vaccines opened new avenues mainly settings low resources where cold chain used conventional logistics is challenge. However, optimization protein yield stability, complexity purification processes, regulatory hurdles are some challenges that still remain. review discusses current status development using operational mechanisms plant platforms, major applications prevention infectious diseases, developments, nanoparticle-mediated cancer vaccines. The discussion will also touch on ethical considerations, framework, future trends respect transformative plant-derived ensuring greater accessibility cost-effectiveness vaccination. field holds great promise disease area and, indeed, personalized medicine biopharmaceuticals near future.

Language: Английский

Citations

2
mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV DOI Creative Commons
Laura Matarazzo, Paulo Bettencourt

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: April 24, 2023

The success of the first licensed mRNA-based vaccines against COVID-19 has created a widespread interest on mRNA technology for vaccinology. As expected, number in preclinical and clinical development increased exponentially since 2020, including numerous improvements formulation design, delivery methods manufacturing processes. However, faces challenges such as cost raw materials, lack standardization, optimization. MRNA may provide solution to some emerging infectious diseases well deadliest hard-to-treat malaria, tuberculosis, human immunodeficiency virus/acquired syndrome (HIV/AIDS), which an effective vaccine, easily deployable endemic areas is urgently needed. In this review, we discuss functional structure, processes vaccines. We up-to-date overview diseases, immunogenicity, efficacy correlates protection vaccines, with particular focus research tuberculosis HIV.

Language: Английский

Citations

41
An Overview of the Use of Nanoparticles in Vaccine Development DOI Creative Commons
Daniel Lozano, Vicente Larraga, Maria Vallet‐Regí

et al.

Nanomaterials, Journal Year: 2023, Volume and Issue: 13(12), P. 1828 - 1828

Published: June 9, 2023

Vaccines represent one of the most significant advancements in public health since they prevented morbidity and mortality millions people every year. Conventionally, vaccine technology focused on either live attenuated or inactivated vaccines. However, application nanotechnology to development revolutionized field. Nanoparticles emerged both academia pharmaceutical industry as promising vectors develop future Regardless striking nanoparticles vaccines research variety conceptually structurally different formulations proposed, only a few them advanced clinical investigation usage clinic so far. This review covered some important developments applied technologies last years, focusing successful race for preparation lipid employed anti-SARS-CoV-2

Language: Английский

Citations

27